Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study.

Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, Otto T, Gerullis H.

Int J Mol Sci. 2018 Dec 2;19(12). pii: E3841. doi: 10.3390/ijms19123841.

2.

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.

Rabien A, Ratert N, Högner A, Erbersdobler A, Jung K, Ecke TH, Kilic E.

Int J Mol Sci. 2018 May 31;19(6). pii: E1622. doi: 10.3390/ijms19061622.

3.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
4.

Illumination of a Vision-How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research.

Ecke TH, Otto T.

Int J Mol Sci. 2017 Nov 19;18(11). pii: E2463. doi: 10.3390/ijms18112463.

5.

miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.

Ecke TH, Stier K, Weickmann S, Zhao Z, Buckendahl L, Stephan C, Kilic E, Jung K.

Cancer Med. 2017 Oct;6(10):2252-2262. doi: 10.1002/cam4.1161. Epub 2017 Sep 6.

6.

Presentation of a method at the Exploration Stage according to IDEAL: Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia is a feasible and effective method - retrospective analysis of 439 patients.

Ecke TH, Barski D, Weingart G, Lange C, Hallmann S, Ruttloff J, Wawroschek F, Gerullis H.

Int J Med Sci. 2017 Feb 25;14(4):302-309. doi: 10.7150/ijms.17963. eCollection 2017.

7.

UBC® Rapid Test for detection of carcinoma in situ for bladder cancer.

Ecke TH, Weiß S, Stephan C, Hallmann S, Barski D, Otto T, Gerullis H.

Tumour Biol. 2017 May;39(5):1010428317701624. doi: 10.1177/1010428317701624.

PMID:
28468590
8.

Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia.

Gerullis H, Ecke TH, Barski D, Bantel C, Weyland A, Uphoff J, Jansen T, Wawroschek F, Winter A.

J Int Med Res. 2017 Apr;45(2):714-722. doi: 10.1177/0300060516684721. Epub 2017 Feb 13.

9.

Protocol for a Randomized Phase II Trial for Mesh Optimization by Autologous Plasma Coating in Prolapse Repair: IDEAL Stage 3.

Gerullis H, Barski D, Georgas E, Borós M, Ramon A, Ecke TH, Selinski S, Luedders D, Kramer MW, Winter A, Wawroschek F, Otto T.

Adv Ther. 2017 Apr;34(4):995-1006. doi: 10.1007/s12325-017-0493-z. Epub 2017 Feb 23.

PMID:
28233277
10.

Transvesical Suprapubic Externalization of Ureteral Stents - Introduction of a Surgical Innovation at the Development Stage.

Gerullis H, Schwartmann K, Ecke TH, Georgas E, Herberg P, Winter A, Wawroschek F, Barski D, Otto T.

Urol Int. 2017;99(1):69-76. doi: 10.1159/000458709. Epub 2017 Feb 22.

PMID:
28222442
11.

Successful evacuation of large perirenal hematoma after extracorporeal shock wave lithotripsy (ESWL) - step 1 of the IDEAL recommendations of surgical innovation.

Hallmann S, Petersein J, Ruttloff J, Ecke TH.

Clin Case Rep. 2017 Jan 16;5(2):123-125. doi: 10.1002/ccr3.792. eCollection 2017 Feb.

13.

Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

Ecke TH.

Adv Exp Med Biol. 2015;867:293-316. doi: 10.1007/978-94-017-7215-0_18. Review.

PMID:
26530373
14.

Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.

Ecke TH, Arndt C, Stephan C, Hallmann S, Lux O, Otto T, Ruttloff J, Gerullis H.

Anticancer Res. 2015 May;35(5):2651-5.

PMID:
25964541
15.

Clinical and pathological features of metastatic adenocarcinoma of the prostate to the ileum.

Ecke TH, Koch S, Ruttloff J, Hallmann S.

Cent European J Urol. 2014;67(4):357-60. doi: 10.5173/ceju.2014.04.art8. Epub 2014 Dec 5.

16.

Urinary thiosulfate as failed prostate cancer biomarker - an exemplary multicenter re-evaluation study.

Stephan C, Wilkosz J, Różański W, Ecke TH, Lein M, Bryś M, Krześlak A, Chwatko G, Jung K.

Clin Chem Lab Med. 2015 Feb;53(3):477-83. doi: 10.1515/cclm-2014-0729.

PMID:
25274944
17.

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.

Clin Genitourin Cancer. 2013 Sep;11(3):346-52. doi: 10.1016/j.clgc.2013.04.010. Epub 2013 May 11.

PMID:
23673281
18.

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.

Urol Oncol. 2014 Jan;32(1):30.e15-21. doi: 10.1016/j.urolonc.2012.11.001. Epub 2013 Feb 18.

PMID:
23428534
19.

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.

Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T.

Anticancer Drugs. 2013 Apr;24(4):422-5. doi: 10.1097/CAD.0b013e32835efe78.

PMID:
23407060
20.

We need to know the treatment of urethral of injuries.

Ecke TH.

Cent European J Urol. 2013;66(3):359-60. doi: 10.5173/ceju.2013.03.art30. No abstract available.

Supplemental Content

Loading ...
Support Center